ClinicalTrials.gg
RecruitingNCT06930677Updated Nov 19, 2025

Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

An interventional study of embolization therapy in Knee Osteoarthritis (Knee OA), sponsored by Next Biomedical Co., Ltd.. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Next Biomedical Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.

Planned enrollment
22nd of 38
72 · median 86
Started
2025
with 2 others
No phase
25 of 46
6 open now
Primary completion
2027-02
later than 7 of 10 live
Registered
43rd of 46
by date

Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 22nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 25 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 43rd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Osteoarthritis, Knee with a site in Belgium, or all of them as a file.
02

Study summary

Study in patients with knee osteoarthritis treated by embolization using NBGM200

03

Conditions studied

  • Knee Osteoarthritis (Knee OA)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis proven by MR-imaging

Exclusion criteria

Exclusion Criteria:

  • Current local infection
  • less than 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    MSK embolization

    Device: embolization therapy

Interventions

  • Deviceembolization therapy

    MSK embolization

06

What researchers measure

Primary outcomes

  1. Knee Injury and Osteoarthritis Outcome score (KOOS-12)

    Knee Injury and Osteoarthritis Outcome score (KOOS-12) is to evaluate the pain, function and quality of life. The total score ranges from 0 to 100, where higher scores indicate better outcomes.

    Time frame: 6 months post treatment

Secondary outcomes

  1. Visual Analog Scale(VAS)

    Visual Analog Scale(VAS) is to evaluate the pain from 0 to 10. Higher scores indicate worse outcomes, representing more severe pain

    Time frame: 6 months post treatment

  2. Whole Organ Magnetic Resonance Imaging Score (WORMS)

    Whole Organ Magnetic Resonance Imaging Score (WORMS) is a semi-quantitative scoring method for multi-feature, whole-organ evaluation of knee OA based on MRI. The total score ranges from 0 to 332, with higher scores indicating worse outcomes.

    Time frame: 6 months post treatment

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 22 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
Apr 17, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06930677
Lead sponsor
Next Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Apr 17, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion